Podcasts about Niagara

More oppressive heat is on the way Wednesday. Meteorologist Aaron Reynolds has the forecast.

The story so far: After being trapped under ground for over a year in a mysterious movie store called "Moleman's Movie Hole," the boys still find ways to entertain themselves...typically with movies.This week, Eric's back! And after mistakingly grabbing the wrong movie off the shelf, we sit back to watch the 1986 horror/thriller classic The Hitcher! Come for the discussion on the greatness of Rutger Hauer, stay for the tangents about Eric's hitchhiking stories, where bodies would realistically get torn apart, and Dan's cool wife and their Niagara vacation! Hop in, we're taking a ride together! Leave us a 30 second voicemail and if we like it we'll play it on the show: (949) 4-STABBY (949-478-2229)Next movie announced every Wednesday. New episodes every Monday. Follow us on the things: Linktree: https://www.linktr.ee/stabbystabbyInstagram:  @stabbypod  https://www.instagram.com/stabbypod/Letterboxd:   https://boxd.it/dp1ACMerch: https://www.big-other.com/shop/stabby-stabbySend us a text

In this episode Cando sits down with local legends of Niagara at Niagara Quartermaster's Airsoft Fest! https://www.instagram.com/pimpchimpers/https://www.instagram.com/bone.apple.teeth.bakery/For excellent beard or skin care products, click the following link for 18% off https://watsonslade.ca/discount/CANDOPEW Powered by - Blackcell Promotions Set Media Keanu's Corner The Compound Eventshttps://linktr.ee/TheCandoExperiment Email us at - thecandoexperiment@gmail.com Links in no particular order - https://ravenevolution.comhttps://thecompoundevents.ca/https://www.instagram.com/canadianairsoftleague/https://open.spotify.com/show/0KZnGH9twkuFoYmTg3CYKU?si=ce4663fea34d461bhttps://www.facebook.com/ElliottLaserCreations/ https://www.facebook.com/CryeWolfAirsoft/ https://instagram.com/seam_ripper_solutions?utm_medium=copy_link https://instagram.com/galeforce_airsoft?utm_medium=copy_link https://instagram.com/crye_wolf_airsoft_?utm_medium=copy_link https://niagaraquartermaster.com/ https://dmzcanada.com/ https://andysairsoft.ca/https://www.instagram.com/thehouseofoakley/https://amplifieddesign.ca/https://www.instagram.com/blackwell_operations_group/https://www.instagram.com/inc.airsoft/https://www.instagram.com/widowmakers_airsoft/

On this weeks bonus episode of OFF AIR we discuss classic game shows, funny athlete names, how many gatherings do we need and Lew has a mouse.

Articles and features from the Island Dispatch and the Niagara Tribune

Top stories from issues of the past week's Niagara Gazette

The grace of God is always flowing, always constant, always cascading – just like the Bible describes it. -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Colton Lackey, Development Director at Niagara Gospel Mission tells us how the nonprofit was able to recover so quickly.

Niagara Frontier Automobile Dealers Association President Paul Stasiak weighs in on Big Beautiful Bill's potential impact on car buying bonus 322 Tue, 08 Jul 2025 09:00:00 +0000 Hy0ypyMf2m4wTqw47FckclcF2Aa4GKud news WBEN Extras news Niagara Frontier Automobile Dealers Association President Paul Stasiak weighs in on Big Beautiful Bill's potential impact on car buying Archive of various reports and news events 2024 © 2021 Audacy, Inc. News

On this week's OFF AIR, the worst hockey nickname, was Helen Keller a scam, which celebs would be good hangs and the best of medieval torture. ENJOY!

Articles and features from the Island Dispatch and the Niagara Tribune

Top stories from issues of the past week's Niagara Gazette

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain, both practicing community oncologists, are joined by Dr. Tian Zhang from UT Southwestern to discuss key highlights from the ASCO 2025 annual meeting, focusing on genitourinary (GU) malignancies. Episode Highlights: • KEYNOTE-564: discussed 5 years OS data, reinforcing the role of adjuvant pembrolizumab in renal cell carcinoma • AMPLITUDE: combination of PARP inhibitor niraparib with abiraterone improved progression-free survival in patients with homologous recombination repair mutations in metastatic hormone-sensitive prostate cancer • ARANOTE: positive quality of life impact when using darolutamide in metastatic hormone-sensitive prostate cancer, which is also FDA approved now • NIAGARA: the prognostic value of ctDNA in muscle-invasive bladder cancer, emphasizing its implications for treatment strategies YouTube: https://youtu.be/Rt8HQpdyVY0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Join us as we break down these important studies and their potential to change clinical practice in oncology. Don't forget to check out our other episodes for more insights into cancer care!

Welcome back to another edition of The 'X' Zone Radio Show with Rob McConnell, broadcasting across Canada, the United States, and around the world from our studios in Niagara, Ontario. Tonight, we are honored to welcome a truly extraordinary guest — Rabbi Rami Shapiro — a rabbi, author, spiritual teacher, and philosopher whose work transcends religious boundaries and dogma to speak directly to the human soul. Rabbi Rami has written over thirty books on religion, spirituality, and ethics, and is known for his deep insights, candid irreverence, and unwavering commitment to spiritual authenticity. Through his Substack newsletter at rabbirami.substack.com, he explores what it means to live wisely, love fiercely, and awaken to the sacred that pervades all things. Whether you're religious, spiritual-but-not-religious, a seeker, or a skeptic — get ready for a deeply thoughtful, often humorous, and always profound conversation. Joining us now on The 'X' Zone is Rabbi Rami Shapiro.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-x-zone-radio-tv-show--1078348/support.

WBEN's Tom Puckett on a food crisis for Niagara Gospel Mission full 59 Wed, 02 Jul 2025 07:55:00 +0000 FULJdzduAMDKUm6tU8HRxrhGFe7j2rzv news & politics,news WBEN Extras news & politics,news WBEN's Tom Puckett on a food crisis for Niagara Gospel Mission Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False https://player.amperwavepodcas

Colton Lackey with Niagara Gospel Mission on a need for food donations after freezer accidents over the weekend full 233 Wed, 02 Jul 2025 07:58:00 +0000 A9tUIYH6Ap0TJWlXT7QkNEGjKfz2vPJK news & politics,news WBEN Extras news & politics,news Colton Lackey with Niagara Gospel Mission on a need for food donations after freezer accidents over the weekend Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News False

Happy Canada Jay Day.  It's July 1, 2025 and for most people it's a holiday and a chance to  barbecue, picnic, get away from the house and watch or set off fireworks after dark.  For birders,(those poor souls that have to work for a living during the week), it's a day to celebrate birds and go birding with friends, family, or just get away on your own and and listen to the summer breeding birds in a quiet forest, park or glen.  As I write this, I'm sitting on a quiet bench in Long Point, Ontario at the Long Point Bird Banding Demonstration Station at what they call the Old Cut.          Since last we visited, a lot has gone on in the birding world here in Southwestern Ontario.  I still have yet to see a Wilson's Warbler, but hopefully fall migration will bring one my way.  Aside from that, the last month has been good to me.  I saw a Laughing Gull in Toronto and Sue and I found, and listened to an Acadian Flycatcher in the oddly named Skunk's Misery.  The other amazing happening, has been an eruption of American White Pelicans that have refused to fly north and west to their breeding grounds.  They've been spotted all over southwestern Ontario.  The big news for the local birders, was that 9 of those pelicans are visiting us where I live in Brantford.  They first appeared on the Grand River at Waterworks Park, only minutes from home. And happily, this batch of, perhaps bachelor pelicans, has stuck around and may, verily, spend the summer with us on The Grand.      I only added 11 birds to my year list in June, many of those I should have seen during migration.  But not that sinker, the Willson's Warbler.  Look, I can understand missing a Worm Eating Warbler,(and yes,I confess I missed that one too), but for Audubon's sake, really, one of the easiest spring warblers, the bright yellow bird with the black yarmulka, described by American ornithologist Alexander Wilson in 1811!  And it's a bird that seems to have little fear of peoples as it hunts bugs and such in the outsides of branches, like dogwoods, in the spring.  So yeah, am I bitter?  Heck yeah!       Okay, take a deep breath. Center yourself.  Breath. It's just one bird.  Not like I missed a Brown Pelican.  Oh yeah, a Brown Pelican showed up in the Niagara region this past Monday. I raced to Niagara-on-the Lake, searched the buoy it had been on, but the heat haze made it impossible to be sure I was looking at it, maybe it was there, maybe it wasn't. By the time I was able to see the  buoy clearly in the afternoon, it was long gone.  But missed opportunities lead to future celebrations when you finally do see the bird you've been searching for all year.  Your patience,(and mine),may one day be rewarded.      Now on to the show.  My guests are a birding couple from Maine, Ingrid and Ethan Whitaker.  Ethan set the record,(since broken), for a Maine Big Year on his own and then Ingrid got into the Big Year spirit so they could see the country, maybe see 600 species of birds, and, for some reason, a giant ball of twine.  They weren't chasing any records, but were more successful than they ever imagined when they set out on their Lower 48 Big Year.  Please enjoy as Ethan and Ingrid Whitaker tell the rest of the story.      Next month, we'll be venturing back in time to the year 2012 and returning to Ontario.  At the beginning of that year I was a 51 yr old, less than novice birder and had started an ABA Big Year on a wing and a prayer.  My guest, however, not even half my age at the time, was an experienced and knowledgeable birder and was setting out on his Ontario Big Year.  It ended up being a battle worth of Kenn Kauffman and Floyd Murdoch back in 1973.  Suffice it to say, my guest, Andrew Keaveny, played the part of Kenn Kauffman.  During the course of 2012 I got to know Andrew very well, and often I was able to follow up on his finds and get birds I may not have seen otherwise.  We have become good birding friends over the years and it will be nice to finally hear his story.      Once again, I wish I could thank everyone personally for listening.  You could do me a big favour by following, subscribing, liking and commenting, wherever it is you listen to my voice over the ethereal land of podcasts.  Also, please tell all your birding friends and family to come have a listen.  Won't you?  

How could a potential change in policy over police pursuits affect the way local law enforcement operates? Some thoughts from Niagara County Sheriff Michael Filicetti full 437 Mon, 30 Jun 2025 11:50:00 +0000 0bicJMthtI9Py6DodgEcwZ9moHQBGejS news,wben,niagara county,michael filicetti,police pursuits A New Morning news,wben,niagara county,michael filicetti,police pursuits How could a potential change in policy over police pursuits affect the way local law enforcement operates? Some thoughts from Niagara County Sheriff Michael Filicetti Collection of LIVE interviews from Buffalo's Early News on WBEN 2024 © 2021 Audacy, Inc. N

On this weeks episode of OFF AIR, we get into classic school pranks, we saved a mayor's career, Chris' sweat don't stink and Lew is turned on by the national anthem.

Articles and features from the Island Dispatch and the Niagara Tribune

O novo episódio do Autorama Podcast traz detalhes sobre a Renault Niagara, a picape médio-compacta que já entrou no forno e quer quer peitar a Fiat Toro. Tem também o novo BMW Série 2 Gran Coupé de malas prontas para o Brasil com uma maravilhosa versão esportiva. Falamos ainda da série limitada do Haval H6 que ganha detalhes exclusivos, mas... perde equipamentos. No quadro retrovisor André Deliberato relembra o Fusca com câmbio automático de fábrica! E a nossa agenda de encontros de carros antigos e clássicos.O Autorama Podcast tem produção e apresentação de Fernando Miragaya.Acesse www.colmeiapodcast.com.br/autorama e siga o nosso perfil no Facebook, no Instagram e no Telegram. Veja fotos incríveis dos assuntos destacados em cada episódio do Autorama! Visite www.colmeiapodcast.com.br Assista também o Autorama TV no YouTube. O novíssimo episódio traz a avaliação do VW ID.Buzz.Assista em https://www.youtube.com/watch?v=Wu34DnwAeGcAutorama! Eleito duas vezes o melhor podcast pelo Jornalistas & Cia - Mais Admirados da Indústria Automotiva.

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

The Outer Realm welcomes the return of dear Friend and special guest, Niagara Historian Dave Bennison Host: Michelle Desrochers Date: June 24th, 2025 Episode: 580 Discussion : Part 2 - Dave is well versed and well researched. He will be sharing a lot of historical information about the Niagara Region, just in time for tourist season! War of 1812, Butlers Rangers, The Forts throughout the Niagara Falls Region, The St Lawrence Seaway/Welland Canal, The Near Full Mastadon Skeleton found in Wainfleet, Ontario and now lies at the Royal Ontario Museum in Toronto, Laura Secord and much more!!! Contact for the show - theouterrealmcontact@gmail.com Rumble: TheOuterRealm X - MicheleDerocher Website: www.theouterrealmradio.com Please support us by Liking, Subscribing, Sharing and Commenting. Thank you all !!! About Dave : Dave is Is a 28 year veteran Truck driver who a few years ago started a side project as a Radio host interviewing Celebrities. Artists Musicians Historians And Paranormal experts His love of History sparked the creation of an Online Webseries called Historical Niagara that has become very popular .Each week exploring The History of Southern Ontario and Western New York. Dave lives in Welland Ont and Also carves Staffs ,Canes and pendants made from Historic wood. His Wife Victoria even wrote a book about it Called Stick to the Story . Social Media FB https://www.facebook.com/HistoricalNiagara?mibextid=LQQJ4d If you enjoy the content on the channel, please support us by subscribing: Thank you All A formal disclosure: The opinions and information presented or expressed by guests on The Outer Realm Radio and Beyond The Outer Realm are not necessarily those of the TOR, BTOR Hosts, Sponsors, or the United Public Radio Network and its producers. Although the content may be interesting, it is deemed "For Entertainment Purposes" . We are always be respectful and courteous to all involved. Thank you, we appreciate you all!

A rare historic ghost from a Soldier's Log while stationed at Fort Mississauga in Niagara-on-the-Lake.  Rare for a good reason … leading to a fun Daniel rant at the end of the episode. Dive into some interesting history, with a local legend author from town and the War of 1812.--- COMMENT AND READ ARTICLES CONTACT FORM

What makes old Malbec vines planted in the 1920s so rare and valuable today? Why would a Canadian winemaker head to Mendoza, Argentina, to start a winery? What's one of the biggest challenges holding back Canadian wine and how can consumers change that? In this episode of the Unreserved Wine Talk podcast, I'm chatting with Ann Sperling & Peter Gamble. You can find the wines we discussed at https://www.nataliemaclean.com/winepicks   Highlights What makes Devotion different from other On Seven wines? What inspired Peter to look beyond Canada to Argentina for winemaking? How did he decide on the particular vineyard to purchase? What is massal selection in viticulture? How did Versado end up with such old vines, and how does this show up in the wine? Are there aspects of Malbec that are similar to Pinot? How have Ann and Peter revitalized the Leily Winery? What are the differences and similarities between Leily and On Seven Chardonnays? What would Ann and Peter like their legacies to be in the Canadian wine industry? What are the greatest threats to the Canadian wine industry? Which three figures in the wine industry would Peter invite to a dream dinner party?   Key Takeaways In the 1905 to 1925 period in Argentina, winemakers at the time planted the greatest genetic diversity amongst the Malbec vines, because they were still learning about it. Their Versado vineyard reflects that time when genetic diversity was appreciated. We visited a lot of wine regions in the world for the meetings, both fun and a necessity, and one of them was Mendoza and loved the climate - a really interesting climate from the point of view of creating flavors and grapes, and really liked the lifestyle as well. We essentially decided it'd be interesting to do something small there that also gives us a second harvest during New Year's. So we can practice twice as often. That was the driver, the potential quality there. They've been talking about this for probably the 40 years that they've been making wine and and they want to figure out how to have lasting consumer engagement. They have a lot of devoted buyers, but they also know kind of the monopoly culture is that, well, if the wine you were looking for today isn't on the shelf, you can buy something else. Promoting the message of buying directly from the wineries, and if you want to try that wine that's made in Nova Scotia or BC, that you actually can order it and have it shipped to your home province. Those interprovincial trade barriers aren't real. There's lots of wine shipping that's taking place already. Just get on your computer like you do with so many other products that you buy and buy online.   About Ann Sperling & Peter Gamble Often referred to as the “power couple” of the Canadian wine industry, Peter Gamble and Ann Sperling have long pursued the pinnacles of wine quality in Canadian vineyards and wineries. Following her upbringing on her family's Okanagan Valley vineyard, Ann turned to the soil for the character and complexity of her wines. Acknowledged as a Canadian pioneer of organic and biodynamic viticulture, ‘terroir' was at the centre of her philosophy and she is renowned for her head winemaking roles at Malivoire, Southbrook, and Sperling Vineyards. Peter, a lifetime wine industry professional, has worked alongside Canada's most passionate winemakers to achieve greater heights with our finest appellation wines. Since 2000, Peter has provided expertise in ultra-premium winemaking operations, including: Stratus, Ravine, Benjamin Bridge and Lightfoot & Wolfville. With the purchase of a top-flight ancient Malbec planting in Mendoza, Argentina, in 2008, Ann and Peter broadened their winemaking activities, but Niagara remains their cherished home base. Current focus is on these Niagara projects: On Seven, Lailey and Stonebridge Vineyards and Dobbin Estate.         To learn more, visit https://www.nataliemaclean.com/343.

It occurred to me that I've never posted a recording from Mansion House as a Soul Shack mix, so I figured with me playing there this Saturday for The Grape & Wine Festival (old, but I am there this Friday for Canada Day weekend), why not post my mix from when I was there in August. Most of the time I get to play inside (instead of the patio) which gives me the freedom musically to play like this mix (as opposed to the patio, where I would need to play more mainstream party bangers for the college crowd). So check it out, hope you enjoy, and if you're in Niagara, come see me this Friday June 27th for Canada Day! (and if you're anywhere in Niagara, Hamilton or The GTA and need a dj for a wedding, birthday or summer party, give me a call!)Subscribe on Apple Podcasts: https://podcasts.apple.com/podcast/id306968245Follow on Instagram: https://www.instagram.com/dj_j_meBookings & Merch: jamiewichartz @ yahoo.ca

Wait, is the main reason Westcott Vineyards exists in our lives is because the owners, Carolyn and Grant don't like to golf??? Okay that may be a wee bit overly simplistic BUT it is part of the story. Check out my interview with Carolyn Hurst, Westcott Vineyards President & Co-Founder where we go into the whole story of this Niagara based winery.

Gov. Kathy Hochul directs the New York Power Authority to develop a zero emission, advanced nuclear power plant in Niagara County full 1364 Mon, 23 Jun 2025 15:00:32 +0000 erdjuuNwGRilArAvBYBZdtggjhINznTI news,kathy hochul,new york state,wben,niagara county,lewiston,new york power authority,news & politics WBEN Extras news,kathy hochul,new york state,wben,niagara county,lewiston,new york power authority,news & politics Gov. Kathy Hochul directs the New York Power Authority to develop a zero emission, advanced nuclear power plant in Niagara County Archive of various reports and news events 2024 © 2021 Audacy, Inc. News & Politics News

This week on your bonus OFF AIR episode Lew is back. We get into Golf, Religion and good ole moustache rubbin'. 

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

You know how when you have a good idea, you get a little lightbulb over your head? What if you had a bad idea, and a million cubic feet of rock collapsed on you.On today's episode: why the tourist bureau for today's story drink so much; how the people in today's episode work with equipment that would rattle an melt your skull off and sometimes want to cry and eat each other; and why the phrase “well, I'm glad that's all over” is rarely misapplied this badly.And because you are listening to this as a Patreon supporter, you get to enjoy an additional 10 minutes where we discuss: the hodge podge of brutalized bones and missing appendages that have sailed over the Falls; you'd hear about the increasingly ill-conceived and sketchy reasons people have tried their luck over the Falls on purpose; you would hear the tales of two waterways widely described as “inhospitable to human survival; and you would learn about the only unintentional subaquatic river trolley in the world.Niagara Falls has always been a magnet for honeymooners, daredevils, stunt performers and industrialists, but there is no place more ready to delete you from your travel itinerary in so many permanent and awful ways. It's also been a magnet for nature-inspired calamity. This is our second episode from this exotic location, and I could do an entire episode on just the daredevils alone. I really wanted to record this episode at Niagara Falls, but I also wanted to get it out in the first half of 2025, so no dice. That said, you can't do an episode about Niagara Falls without talking about the numbers of people who “take that vertical swim” on purpose.If you or someone you know sounds like they'd like to visit the Falls so-to-speak, please don't hesitate to reach out. There are people ready to help.In Canada, Talk Suicide Canada at 1-833-456-4566 (Available 24/7) or text 45645, or visit www.crisisservicescanada.ca. For youth and young adults, there is also Kids Help Phone at 1-800-668-6868 or text CONNECT to 686868.In the United States, you can call the 988 Suicide & Crisis Lifeline: just dial 988 (Available 24/7) or you can text HOME to 741741In the UK, you can reach the Samaratins at 116 123.Obviously, this kind of thing that can be hard to talk about, but this is a show filled with things that can be hard to listen to. You're already brave. Use that bravery to pick up a phone and please take care of yourself. All older episodes can be found on any of your favorite channelsApple : https://tinyurl.com/5fnbumdw Spotify : https://tinyurl.com/73tb3uuw IHeartRadio : https://tinyurl.com/vwczpv5j Podchaser : https://tinyurl.com/263kda6w Stitcher : https://tinyurl.com/mcyxt6vw Google : https://tinyurl.com/3fjfxatt Spreaker : https://tinyurl.com/fm5y22su Podchaser : https://tinyurl.com/263kda6w RadioPublic : https://tinyurl.com/w67b4kec PocketCasts. : https://pca.st/ef1165v3 CastBox : https://tinyurl.com/4xjpptdr Breaker. : https://tinyurl.com/4cbpfayt Deezer. : https://tinyurl.com/5nmexvwt Follow us on the socials for moreFacebook : www.facebook.com/doomsdaypodcast Instagram : www.instagram.com/doomsdaypodcast Twitter : www.twitter.com/doomsdaypodcast TikTok : https://www.tiktok.com/@doomsday.the.podcast If you like the idea of your podcast hosts wearing more than duct tape and bits of old Halloween costumes for clothes and can spare a buck or two, you can now buy me a coffee at www.buymeacoffee.com/doomsday or join the patreon at www.funeralkazoo.com/doomsday

Dateline: June 20, 2025. Rossifari Zoo News is back with a round up of the latest news in the world of zoos, aquariums, conservation, and animal weirdness!   We start off with a quick catch up on me. We then move on to our births for the week, featuring animals from Aquarium of Niagara, Southwick's Zoo, Zoo Miami, Sequoia Park Zoo, Franklin Park Zoo, Minnesota Zoo, Binder Park Zoo, and more.We then say goodbye to animals from Buttonwood Park Zoo, Denver Zoo, Hogle Zoo, Adelaide Zoo, and Chattanooga Zoo.We have additional Zoo News stories from the Columbus Zoo, Smithsonian's National Zoo, Perth Zoo, Fort Worth Zoo, Trevor-Lovejoy Zoo, and more! Conservation News stories includes updating pangolin protections, a rediscovery, and more! And in Other News, it's Ed the zebra.ROSSIFARI LINKS: patreon.com/rossifari to support the pod rossifari.com @rossifari on socials @rossifaripod on TikTok 

Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Centre, Madrid, joins us. This is a mega episode where we cover AMPLITUDE, JAVELIN MEDLEY, CHECKMATE 901 and NIAGARA, advancing urothelial cancer care; SEAR 02 and the CReST trial, pushing boundaries in bladder cancer; CHECKMATE 214; LITESPARK-005 and LITESPARK-004, showcasing belzutifan's promise; and KEYNOTE-564, adjuvant therapy for kidney cancer. Stay tuned for an insightful conversation on how these trials may be transforming patient outcomes!Studies discussed in the episode:CHECKMATE 901NIAGARACHECKMATE 214CREST trialSEAR 02LITESPARK 004/005AMPLITUDEJAVELIN MEDLEYFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

What were the key challenges and breakthroughs that shaped the BC and Ontario wine industries in the 1980s and 90s? What makes or breaks a new wine project, and why is finding the right vineyard often the most time-consuming step? What made Peter believe that Niagara-on-the-Lake could produce exceptional Chardonnay? In this episode of the Unreserved Wine Talk podcast, I'm chatting with Ann Sperling & Peter Gamble. You can find the wines we discussed at https://www.nataliemaclean.com/winepicks   Highlights What was Ann's best memory from growing up on the farm? When did Ann and Peter know that they wanted to work in the wine industry? How did Ann and Peter meet? What was the first bottle of wine Ann and Peter shared? How do Ann and Peter navigate their interwoven personal and professional lives? How do they negotiate professional disagreements, and who chooses the wine for dinner? What were the major challenges and opportunities in the BC and Ontario wine industry in the 1980s and 90s? In the early days, how did Peter envision the future of Ontario wines? What are some of the reasons certain vintages almost didn't make it into the bottle? What do you look for when considering a new project? What makes Ann and Peter different from the stereotypical flying winemakers? What were the signs that Niagara-on-the-Lake could produce exceptional Chardonnay? How has working on a small, focused vineyard impacted Ann and Peter's winemaking choices? Why must you suffer to make top-notch wines?   Key Takeaways It was in the early 80s in BC and maybe slightly before that in Ontario, that estate wineries became a thing. Prior to that, that meant there were a few really large wineries, not really making estate or single vineyards. Vineyards were a source of bulk wine for the most part. The hunt for the vineyard became a very important one. We looked at over 230 vineyards before we found one. I think everyone there was on the verge of giving up on this, thinking “Well, they're not really going to buy anything.” Because we'd get it to a certain stage, then we do soil analysis, and we weren't quite happy, or we talked to people who had made wine from the vineyard or something would come up, and we just wouldn't quite be where we wanted to be with the quality of the vineyard. I often work on the basis of paradigms, where I'll take a look at a wine sold throughout the world and say, you know, I think this could be done really well in this area. You know what it is you might be able to accomplish within the parameters that you have - the obvious things, the terroir, the exposures to soils, the temperatures in general.   About Ann Sperling & Peter Gamble Often referred to as the “power couple” of the Canadian wine industry, Peter Gamble and Ann Sperling have long pursued the pinnacles of wine quality in Canadian vineyards and wineries. Following her upbringing on her family's Okanagan Valley vineyard, Ann turned to the soil for the character and complexity of her wines. Acknowledged as a Canadian pioneer of organic and biodynamic viticulture, ‘terroir' was at the centre of her philosophy and she is renowned for her head winemaking roles at Malivoire, Southbrook, and Sperling Vineyards. Peter, a lifetime wine industry professional, has worked alongside Canada's most passionate winemakers to achieve greater heights with our finest appellation wines. Since 2000, Peter has provided expertise in ultra-premium winemaking operations, including: Stratus, Ravine, Benjamin Bridge and Lightfoot & Wolfville. With the purchase of a top-flight ancient Malbec planting in Mendoza, Argentina, in 2008, Ann and Peter broadened their winemaking activities, but Niagara remains their cherished home base. Current focus is on these Niagara projects: On Seven, Lailey and Stonebridge Vineyards and Dobbin Estate.         To learn more, visit https://www.nataliemaclean.com/342.

Don't let the sad state of mankind discourage you – let that fact energize your sharing of the gospel. -------- Thank you for listening! Your support of Joni and Friends helps make this show possible.     Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org   Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

On this weeks bonus episode of OFF MIC we talk about jerks who send food back, we find out about Lew's body hair regiment and Jason wants to murder fans. Good times.

Articles and features from the Island Dispatch and the Niagara Tribune

Top stories from issues of the past week's Niagara Gazette

Send us a textJochen Weigel from Stuttgart, Germany joins us to discuss his innovative contributions to prosthetics, including post-processing for Niagara feet and the development of the AirFit casting system.• Jochen's journey from clinical specialist to R&D manager to starting his own business 13 years ago• The AirFit system uses air pressure instead of water to create comfortable prosthetic sockets• Air pressure uniquely compresses only soft tissue while preserving bony structures• Testing in Kenya combined the AirFit system with low-temperature thermoplastic sockets for immediate fitting• The Niagara foot provides exceptional durability compared to SACH feet commonly used in developing regions• Made with special DuPont material (Hydrel) through a complex molding process few can replicate• The foot works across weight ranges from 70-190 pounds when properly tuned• High initial cost compared to $20 Chinese alternatives creates adoption challenges despite long-term savings• Ways to help include volunteering with NGOs, making targeted donations, or collaborating with small companiesIf you have ideas for prosthetic products that could help in developing regions, reach out to smaller companies who are more likely to be interested in humanitarian solutions.Special thanks to Advanced 3D for sponsoring this episode.Support the show

This week's episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others. 

Liberty Dispatch Interviews ~June 07, 2025In this episode of Liberty Dispatch Interviews, host Andrew DeBartolo speaks with Harold Jonker, a former Niagara region councillor and a key figure in the Freedom Convoy. They discuss Harold's experiences during and after the convoy, including the legal challenges he faced, the role of the integrity commissioner, and the importance of Christian involvement in politics. In celebration of Harold's legal vindication, enjoy this full interview for free! For full access to all our content, become a paid subscriber at: Liberty Dispatch Substack ldcanada.substack.com Canadian news, culture, and political analysis from a Christian perspective. Episode Resources: Freedom Convoy victory: Trucker Harold Jonker cleared of all charges in Ontario court: https://www.jccf.ca/freedom-convoy-victory-trucker-harold-jonker-cleared-of-all-charges-in-ontario-court/; SHOW SPONSORS: Go to https://PIAVPN.com/LibertyDispatchto get 83% off from our sponsor, Private Internet Access, with 4 months free! Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/ SUBSCRIBE TO OUR SHOWS/CHANNELS: LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD:Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!

Liberty Dispatch Interviews ~June 07, 2025 In this episode of Liberty Dispatch Interviews, host Andrew DeBartolo speaks with Harold Jonker, a former Niagara region councillor and a key figure in the Freedom Convoy. They discuss Harold's experiences during and after the convoy, including the legal challenges he faced, the role of the integrity commissioner, and the importance of Christian involvement in politics.  In celebration of Harold's legal vindication, enjoy this full interview for free! For full access to all our content, become a paid subscriber at: Liberty Dispatch Substack ldcanada.substack.com Canadian news, culture, and political analysis from a Christian perspective. Episode Resources:  Freedom Convoy victory: Trucker Harold Jonker cleared of all charges in Ontario court: https://www.jccf.ca/freedom-convoy-victory-trucker-harold-jonker-cleared-of-all-charges-in-ontario-court/;  SHOW SPONSORS: Go to https://PIAVPN.com/LibertyDispatchto get 83% off from our sponsor, Private Internet Access, with 4 months free! Invest with Rocklinc: info@rocklinc.com or call them at 905-631-546; Diversify Your Money with Bull Bitcoin: https://mission.bullbitcoin.com/dispatch; BarterPay: https://barterpay.ca/; Barter It: https://www.barterit.ca/; Get freedom from Censorious CRMS by signing up for SalesNexus: https://www.salesnexus.com/ SUBSCRIBE TO OUR SHOWS/CHANNELS:  LIBERTY DISPATCH PODCAST: https://libertydispatch.podbean.com; https://rumble.com/LDshow; CONTACT US: libertydispatch@pm.me STAY UP-TO-DATE ON ALL THINGS LD:Instagram: https://www.instagram.com/liberty_dispatch/; Facebook: https://www.facebook.com/LibertyDispatchCanada; X: @LDCanada - https://x.com/_LDCanada; Rumble: https://rumble.com/LDshow; YouTube: https://www.youtube.com/@libertydispatch Please LIKE, SUBSCRIBE, RATE, & REVIEW, and SHARE it with others!

Top stories from issues of the past week's Niagara Gazette

Articles and features from the Island Dispatch and the Niagara Tribune

Our new weekly bonus podcast called OFF MIC. Yes we still use microphones, it's just means not on the radio. Like off camera stuff, but on camera, and on mic...YOU SHUT UP! 

On this episode of Destination on the Left, I talk with Patrick Keyes, Sales and Marketing Manager at Rainbow Air Helicopter Tours in Niagara Falls, about why he believes in coopetition and how collaborations with his competitors have helped him be successful. Patrick explains why being a first call partner to your local and regional DMO is so important, and how you can position yourself to be that partner. He also offers valuable advice on how to work collaboratively at trade shows to build success. What You Will Learn in This Episode: How Patrick developed a regional, visitor-centric mindset by looking beyond traditional industry boundaries Why Patrick firmly believes that coopetition drives success for individual businesses and the broader destination What innovative steps Rainbow Air Helicopter Tours is taking to transform into a year-round, multifunctional attraction, including their new facility and virtual reality experiences Why partnering with local and regional DMOs (Destination Marketing Organizations) allows you to maximize marketing opportunities and industry influence Strategies Patrick uses when attending industry trade shows to represent both his own company and the wider Niagara region, and how this approach builds stronger relationships How Patrick seeks out unconventional partnerships, like collaborations with wineries and golf courses, to create memorable experiences and extend visitor stays in the region Leveraging Collaboration for Year-Round Tourism One of Rainbow Air's boldest moves has been the development of a new 30,000-square-foot tourism center. This ambitious facility isn't just a ticket counter; it's set to become a hub of activity through every season. Traditionally, tourism in Western New York peaks from Memorial Day to Labor Day, but Patrick and his team saw the need for more. The new tourism center, set to open over Memorial Day weekend, will feature a range of amenities, including gift shops, restrooms, and innovative virtual reality attractions, such as parasailing over Niagara Falls. By offering a range of experiences and amenities, Rainbow Air aims to both attract off-peak visitors and encourage them to extend their stays, laying the groundwork for sustainable year-round tourism. The Power of Partnerships A recurring theme throughout Patrick's career is the essential role of strong relationships with Destination Marketing Organizations (DMOs), regional partners, and fellow attractions. As part of Rainbow Air, he is able to attend trade shows globally, but Patrick insists on representing the region, not just his company. “Know your audience, do your research, and come prepared to advocate for not only your attraction, but complementary experiences that round out the destination,” he advises. Forming partnerships with other attractions enables a rising tide that lifts all ships. Being proactive, communicating openly, and showing a genuine commitment to representing the community as a whole are so important. When DMOs trust that you'll be a reliable, high-quality option, you're top of mind for press trips, FAM tours, and state-led opportunities. Creative Collaborations Rainbow Air's vision for cross-industry cooperation doesn't stop at helicopter tours. Patrick is exploring partnerships with local wineries, golf courses, and historical sites. Imagine custom packages where visitors enjoy an aerial tour before being whisked away to a vineyard for a picnic. Or collaborating with the local wine trail for multi-stop experiences. By thinking creatively about what both locals and travelers want, Rainbow Air extends an invitation for everyone to participate in the region's success. What excites Patrick most is not just Rainbow Air's growth, but the chance to be “a beacon” for others in Niagara Falls. By investing in innovation and actively inviting everyone to the table, he hopes to create a mutually beneficial model, one where attractions, large and small, lean on each other to make the region irresistible and vibrant, every season of the year. Resources: Website: https://www.rainbowairinc.com/ LinkedIn: https://www.linkedin.com/in/patrick-keyes-1001186/ We value your thoughts and feedback and would love to hear from you. Leave us a review on your favorite streaming platform to let us know what you want to hear more o​f. Here is a quick tutorial on how to leave us a rating and review on iTunes!

Today, we're going to witness a light so bright it would instantaneously and irreversibly turn your corneas into charcoal, and oddly, it's the least dangerous thing about our story. On today's episode: why the tourist bureau for today's story drink so much; how the people in today's episode work with equipment that would rattle an melt your skull off and sometimes want to cry and eat each other; and why the phrase “well, I'm glad that's all over” is rarely misapplied this badly.And because you are listening to this as a Patreon supporter, you get to enjoy an additional 9 minutes where we discuss: the time we burned down a good chunk of Washington, including the White House; and why you're welcome for it; the time Germany blew up a chunk of New Jersey and Lady Liberty got popped in the boob with a missile; why people through history were ridiculed for believing in waves; and you would hear about an Australian bloke who DIYed himself into one of the most dangerous world records available.This is episode is a staunch reminder of my desire to make sure every episode surprises and delights. A lighthouse? It's not the strangest place we've visited, but it's certainly unexpected. It also checks a lot of boxes for being largely unheard of, bizarre, and forgotten. The Hawaiian experience back in 1946 overwhelmed the public's mind, and no one had time for a building built strong enough to withstand artillery exploding at the touch of mere water. It also hold's a distinction for being a place where people regularly lose it – and we did an episode about an asylum that caught on fire, so that's saying a lot. All older episodes can be found on any of your favorite channelsApple : https://tinyurl.com/5fnbumdw Spotify : https://tinyurl.com/73tb3uuw IHeartRadio : https://tinyurl.com/vwczpv5j Podchaser : https://tinyurl.com/263kda6w Stitcher : https://tinyurl.com/mcyxt6vw Google : https://tinyurl.com/3fjfxatt Spreaker : https://tinyurl.com/fm5y22su Podchaser : https://tinyurl.com/263kda6w RadioPublic : https://tinyurl.com/w67b4kec PocketCasts. : https://pca.st/ef1165v3 CastBox : https://tinyurl.com/4xjpptdr Breaker. : https://tinyurl.com/4cbpfayt Deezer. : https://tinyurl.com/5nmexvwt Follow us on the socials for moreFacebook : www.facebook.com/doomsdaypodcast Instagram : www.instagram.com/doomsdaypodcast Twitter : www.twitter.com/doomsdaypodcast TikTok : https://www.tiktok.com/@doomsday.the.podcastIf you like the idea of your podcast hosts wearing more than duct tape and bits of old Halloween costumes for clothes and can spare a buck or two, you can now buy me a coffee at www.buymeacoffee.com/doomsday or join the patreon at www.funeralkazoo.com/doomsday

Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.